On 15 September 2026, Suzhou Basecare Medical Corporation Limited (Basecare) announced that China’s National Medical Products Administration (NMPA) has granted Class III medical device registration certificates—Nos. Guo Xie Zhu Jin 20263180326 and 20263180338—for the Gems Vitrification Set and Gems Warming Set.

The newly approved products originate from the same R&D platform as Basecare’s Gavi fully automated closed vitrification system. They are compatible both with the widely used Cryotop® carrier in domestic reproductive centres and, with minor adjustments, with the Gavi automated vitrification instrument, enabling integration into both automated and manual laboratory workflows.

Key technical features include: • Dual-permeating cryoprotectant formulation (DMSO + ethylene glycol) that lowers individual agent concentration, reducing embryotoxicity while ensuring effective vitrification and ice-crystal inhibition. • Use of trehalose as the non-permeating cryoprotectant in both the Vitrification and Warming Sets, replacing traditional sucrose. Trehalose stabilises cell membranes and intracellular proteins, offering broader protection during cryopreservation and warming.

With these approvals, the Gems series now comprises certified Oocyte Retrieval Buffer, Sperm Wash Medium, Fertilisation Medium, Cleavage Medium, Blastocyst Medium, Embryo Medium, VitBase embryo processing fluid, and the newly registered Vitrification and Warming Sets. The expanded portfolio covers the complete workflow from gamete processing and embryo culture to cryopreservation and thawing, positioning Basecare as a comprehensive reagent provider for embryology laboratories.

Shareholders and potential investors are advised to exercise caution when dealing in Basecare shares.